Study guide

3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers

Certified Addictions Registered Nurse - Advanced Practice CARN-AP

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice

About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care

2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance

1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene

3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone

2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)

4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal

3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications

5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen

6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders

5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds

7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions

7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice

9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning

8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy

10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines

9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications

10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP

12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing

11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy

12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine

14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education

15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition

14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol

16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support

17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations

16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy

17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM

20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)

20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation

22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction

3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers

Key Takeaways Explain This Topic AI

Acute alcohol acts as a positive allosteric modulator at GABA-A receptors and an antagonist at NMDA glutamate receptors; chronic exposure induces compensatory GABA-A receptor downregulation/uncoupling and NMDA receptor subunit upregulation.

Ethanol stimulates mesolimbic dopamine release in the nucleus accumbens by inducing beta-endorphin release in the ventral tegmental area, which disinhibits dopaminergic neurons via mu-opioid receptors on local GABAergic interneurons.

The AUDIT (10 items; scores ≥8 in men, ≥7 in women indicate hazardous drinking) and AUDIT-C (3 items; cutoffs ≥4 in men, ≥3 in women) are gold-standard screening tools; CAGE (≥2 clinically significant) is specific for severe dependence but lacks sensitivity for early or hazardous drinking.

Phosphatidylethanol (PEth) in whole blood is a direct phospholipid biomarker with a 2 to 4 week detection window and near-100% specificity for heavy drinking (>4 drinks/day), completely unaffected by liver disease, age, or incidental alcohol exposures.

Urine ethyl glucuronide (EtG) and ethyl sulfate (EtS) detect recent alcohol exposure for 24 to 80 hours, but clinical interpretation requires high cutoffs (500 to 1,000 ng/mL) to distinguish intentional ethanol ingestion from incidental environmental exposures like hand sanitizers or mouthwashes.

Last updated: September 2026

3.1 AUD Neurobiology, Epidemiology, Screening Instruments & Laboratory Biomarkers

Quick Answer: Alcohol acutely enhances inhibitory GABA-A receptor currents and inhibits excitatory NMDA glutamate receptors . Chronic heavy consumption triggers neuroadaptive downregulation and conformational uncoupling of GABA-A receptors alongside upregulation of NMDA receptor subunits (NR1, NR2B). In clinical screening, the AUDIT (cutoff ≥8 for men, ≥7 for women) and AUDIT-C (cutoff ≥4 for men, ≥3 for women) are the gold standards for identifying hazardous alcohol use. For objective biomarker monitoring, Phosphatidylethanol (PEth) in whole blood is the most specific direct biomarker for heavy drinking (window: 2–4 weeks; half-life: 4–10 days) and is unaffected by liver disease, whereas urine Ethyl Glucuronide (EtG) detects recent consumption (window: 24–80 hours) but requires a cutoff of ≥500 ng/mL to avoid false positives from incidental environmental exposure.

1. Neurobiology of Alcohol Use Disorder

Alcohol (ethanol) is a small, amphiphilic molecule that diffuses freely across the blood-brain barrier, exerting complex allosteric modulatory effects on ligand-gated ion channels, second messenger systems, and neuroendocrine circuits.

Acute Pharmacodynamic Mechanisms

Unlike classical receptor agonists that bind to primary orthosteric neurotransmitter binding pockets, ethanol exerts its acute central nervous system (CNS) effects through allosteric modulation of multiple membrane-bound protein targets:

GABA-A Receptor Positive Allosteric Modulation (PAM): Ethanol binds to discrete cavity pockets within the transmembrane domains of the GABA-A receptor complex (particularly receptors containing α 1 , α 2 , α 3 \alpha_1, \alpha_2, \alpha_3 α 1 ​ , α 2 ​ , α 3 ​ , or α 5 \alpha_5 α 5 ​ subunits paired with β \beta β and γ 2 \gamma_2 γ 2 ​ subunits, as well as extrasynaptic α 4 β δ \alpha_4\beta\delta α 4 ​ β δ and α 6 β δ \alpha_6\beta\delta α 6 ​ β δ receptors). This allosteric binding increases the open-channel probability and prolongs the duration of inhibitory chloride channel opening in response to gamma-aminobutyric acid (GABA). The resulting intracellular influx of chloride ions hyperpolarizes the post-synaptic neuronal membrane, leading to generalized CNS depression, anxiolysis, sedation, and motor incoordination.

NMDA (N-Methyl-D-Aspartate) Receptor Antagonism: Concurrently, acute ethanol acts as an uncompetitive antagonist at ionotropic NMDA glutamate receptors , specifically targeting the extracellular and channel pore domains of receptors assembled from GluN1 (NR1) and GluN2B (NR2B) subunits. Ethanol suppresses glutamate-stimulated calcium ( C a 2 + Ca^{2+} C a 2 + ) and sodium ( N a + Na^+ N a + ) influx, blunting post-synaptic excitatory postsynaptic potentials (EPSPs). This acute inhibition impairs long-term potentiation (LTP) in the hippocampus, directly mediating alcohol-induced cognitive blunting and blackouts (anterograde amnestic episodes).

Other Ion Channel & Receptor Targets: Ethanol enhances the activity of inhibitory glycine receptors in the brainstem and spinal cord, activates G-protein-coupled inwardly rectifying potassium (GIRK) channels, and facilitates excitatory serotonin 5 − HT 3 5-\text{HT}_3 5 − HT 3 ​ and nicotinic acetylcholine receptors ( n A C h R s nAChRs n A C h R s ).

Chronic Neuroadaptation & Allostasis

With chronic, repetitive, high-dose ethanol exposure, the central nervous system undergoes profound compensatory neuroplastic adaptations in an attempt to restore homeostatic functional balance against sustained ethanol-mediated depression:

GABA-A Receptor Downregulation & Conformational Uncoupling: Chronic exposure leads to endocytosis, internalization, and transcriptional downregulation of post-synaptic GABA-A receptor complexes. Crucially, there is a conformational uncoupling between the GABA binding site and the allosteric benzodiazepine/barbiturate/ethanol binding sites. Subunit composition shifts (e.g., replacement of α 1 \alpha_1 α 1 ​ subunits with α 4 \alpha_4 α 4 ​ or α 6 \alpha_6 α 6 ​ subunits), causing marked tolerance to the sedative and hypnotic effects of GABAergic modulators.

NMDA Receptor & Calcium Channel Upregulation: To counterbalance chronic glutamatergic suppression, neurons increase gene expression and membrane trafficking of NMDA receptor subunits (particularly NR1 and NR2B) and L-type voltage-gated calcium channels. This compensatory increase in NMDA receptor density sensitizes the neuronal architecture to excitatory glutamate.

The Neurochemical Vulnerability: When ethanol is abruptly withdrawn or eliminated from circulation, the persistent, uncoupled, downregulated GABA-A receptors can no longer provide adequate inhibitory tone, while the upregulated, hypersensitized NMDA receptors are suddenly exposed to endogenous glutamate without ethanol-mediated blockade. This uncoupling results in a massive, unopposed excitatory cascade that drives acute alcohol withdrawal, seizures, and excitotoxic neuronal death.

Mesolimbic Dopaminergic Circuitry & Reward Processing

The reinforcing, hedonic, and addictive properties of alcohol are driven by the mesolimbic dopamine pathway , projecting from the ventral tegmental area (VTA) to the nucleus accumbens (NAc) :

Opioid Peptide Intermediation: Ethanol stimulates the local synthesis and release of endogenous opioid peptides, specifically β \beta β -endorphin , within the VTA.

Disinhibition Mechanism: β \beta β -endorphin binds with high affinity to μ \mu μ -opioid receptors (MOR) located on local GABAergic interneurons within the VTA. Activation of MOR hyperpolarizes and inhibits these inhibitory interneurons. By silencing the "brake" of these GABAergic interneurons, the adjacent dopaminergic projection neurons are disinhibited , firing at increased frequencies and discharging a surge of dopamine into the shell of the nucleus accumbens.

Incentive Salience & Craving: Repetitive dopamine surges reinforce ethanol-seeking behavior, converting neutral environmental cues into conditioned stimuli that evoke potent drug craving via recruitment of the basolateral amygdala, hippocampus, and anterior cingulate cortex. [Ethanol Exposure]

  • │
  • ▼
  • [Release of Endogenous β-Endorphin in VTA]
  • │
  • ▼
  • [Activation of μ-Opioid Receptors on GABAergic Interneurons]
  • │
  • ▼ (Inhibition of GABA release)
  • [Disinhibition of VTA Dopaminergic Neurons]
  • │
  • ▼
  • [Dopamine Efflux into Nucleus Accumbens Shell]
  • │
  • ▼
  • [Positive Hedonic Reinforcement & Incentive Salience]
  • 2. Epidemiology & DSM-5-TR Diagnostic Criteria

Alcohol Use Disorder represents one of the leading preventable causes of morbidity, disability-adjusted life years (DALYs) lost, and premature mortality in the United States, implicated in over 140,000 deaths annually.

DSM-5-TR Diagnostic Formulation

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) conceptualizes AUD as a single continuum of problematic alcohol use leading to clinically significant impairment or distress, defined by meeting at least 2 of 11 criteria within a 12-month period across four core domains:

Domain Diagnostic Criteria

Impaired Control 1. Alcohol consumed in larger amounts or over a longer period than intended.; 2. Persistent desire or unsuccessful efforts to cut down or control use.; 3. Great deal of time spent obtaining, using, or recovering from alcohol.; 4. Craving , or a strong desire/urge to use alcohol.

Social Impairment 5. Recurrent use resulting in failure to fulfill major role obligations (work, school, home).; 6. Continued use despite persistent/recurrent social or interpersonal problems caused/exacerbated by alcohol.; 7. Important social, occupational, or recreational activities given up or reduced.

Risky Use 8. Recurrent use in physically hazardous situations (e.g., driving, operating machinery).; 9. Continued use despite knowledge of having a persistent/recurrent physical or psychological problem caused/exacerbated by alcohol.

Pharmacological 10. Tolerance : Need for markedly increased amounts to achieve intoxication/desired effect, or markedly diminished effect with continued use of same amount.; 11. Withdrawal : Characteristic withdrawal syndrome for alcohol, or alcohol (or a closely related substance, e.g., benzodiazepine) is taken to relieve/avoid withdrawal.

Important

Diagnostic Severity Stratification:

  • Mild AUD: Presence of 2 to 3 criteria
  • Moderate AUD: Presence of 4 to 5 criteria
  • Severe AUD: Presence of 6 or more criteria

Note on Prescribed Medications: While criteria 10 (tolerance) and 11 (withdrawal) are not considered met for individuals taking medications strictly under proper medical supervision, this clinical exception applies primarily to prescribed opioids and benzodiazepines rather than recreational alcohol consumption.

3. Validated Clinical Screening Instruments

Early identification through universal, standardized screening in primary care, emergency, and psychiatric settings is a core competency for the Advanced Practice Registered Nurse (APRN).

AUDIT (Alcohol Use Disorders Identification Test)

Developed by the World Health Organization (WHO), the AUDIT is a 10-item questionnaire that assesses three distinct conceptual domains:

  • Hazardous Alcohol Use (Items 1–3: frequency, quantity, and heavy episodic/binge drinking)
  • Dependence Symptoms (Items 4–6: impaired control, increased salience of drinking, morning drinking)
  • Harmful Alcohol Use (Items 7–10: guilt, blackouts, alcohol-related injuries, others concerned)

Scoring Range: Each item is scored 0 to 4, yielding a total score between 0 and 40.

Clinical Cutoffs:

Men (<65 years): Total score ≥ 8 \ge 8 ≥ 8 indicates hazardous or harmful alcohol consumption.

Women and all adults ≥ 65 \ge 65 ≥ 65 years: Total score ≥ 7 \ge 7 ≥ 7 indicates hazardous or harmful alcohol consumption (due to lower gastric alcohol dehydrogenase activity, smaller volume of distribution, and higher percentage of body fat).

Risk Stratification & WHO Intervention Zones:

Zone I (Score 0–7): Low risk / abstinence → Alcohol education.

Zone II (Score 8–15): Medium risk / hazardous use → Brief intervention and education.

Zone III (Score 16–19): High risk / harmful use → Brief intervention, extended counseling, and continued monitoring.

Zone IV (Score 20–40): Probable dependence → Referral to specialized addiction evaluation, diagnostic assessment, and pharmacotherapy initiation.

AUDIT-C (Consumption Subscale)

The AUDIT-C consists exclusively of the first three consumption-oriented questions of the full AUDIT:

  • How often do you have a drink containing alcohol? (0–4 points)
  • How many standard drinks do you have on a typical day when drinking? (0–4 points)
  • How often do you have 6 or more drinks on one occasion? (0–4 points)

Scoring Range: 0 to 12 points.

Validated Cutoffs:

Men: Score ≥ 4 \ge 4 ≥ 4 is positive for hazardous drinking or active AUD (sensitivity ~86%, specificity ~72%).

Women and Older Adults ( ≥ 65 \ge 65 ≥ 65 ): Score ≥ 3 \ge 3 ≥ 3 is positive (sensitivity ~88%, specificity ~80%).

Clinical Utility: Due to its brevity, the AUDIT-C is widely integrated into Electronic Health Record (EHR) clinical decision support workflows and annual wellness visits.

CAGE Questionnaire

The CAGE is a classic 4-question screening mnemonic focused on lifetime behavioral consequences:

C — Have you ever felt you should Cut down on your drinking?

A — Have people Annoyed you by criticizing your drinking?

G — Have you ever felt bad or Guilty about your drinking?

E — Have you ever had a drink first thing in the morning to steady your nerves or get rid of a hangover ( Eye-opener )?

Scoring & Interpretation: Each affirmative answer scores 1 point. A score of ≥ 2 \ge 2 ≥ 2 is considered clinically significant and warrants further diagnostic evaluation (sensitivity 70–85%, specificity 85–95%).

Advanced Practice Limitations: While highly specific for moderate-to-severe lifetime alcohol dependence, CAGE has poor sensitivity for detecting early hazardous drinking, binge drinking, or mild AUD, and cannot differentiate active, current drinking from remote historical dependence.

Comparative Overview of Screening Instruments

Instrument Items Focus / Domain Validated Cutoff Sensitivity / Specificity Primary Clinical Setting

AUDIT 10 Consumption, dependence, and consequences ≥ 8 \ge 8 ≥ 8 (men); ≥ 7 \ge 7 ≥ 7 (women/elderly) Sens: 90%; Spec: 80% Comprehensive primary care, addiction clinics, pre-op clearance

AUDIT-C 3 Alcohol consumption and binge frequency ≥ 4 \ge 4 ≥ 4 (men); ≥ 3 \ge 3 ≥ 3 (women/elderly) Sens: 86–88%; Spec: 72–80% Rapid outpatient screening, EHR intake, acute care settings

CAGE 4 Behavioral impact and physical dependence ≥ 2 \ge 2 ≥ 2 affirmative responses Sens: 70–85%; Spec: 85–95% General medical inpatient floors, psychiatric triage

4. Laboratory Biomarkers of Alcohol Consumption

Biomarkers provide objective, quantitative validation of alcohol intake, resolving diagnostic uncertainty when patient self-reporting is compromised by shame, stigma, memory impairment, or forensic/legal incentives.

Direct Biomarkers

Direct biomarkers are direct non-oxidative metabolites of ethanol synthesized in vivo. Their presence definitively confirms the direct biological exposure to ethanol.

1. Phosphatidylethanol (PEth)

Biochemistry: PEth is an abnormal, direct phospholipid formed exclusively in red blood cell (erythrocyte) membranes through the transphosphatidylation of phosphatidylcholine catalyzed by the enzyme phospholipase D in the presence of ethanol.

Detection Window & Kinetics: Elimination half-life averages 4 to 10 days . The detection window spans 2 to 4 weeks (up to 28 days) following significant alcohol intake.

Clinical Superiority: PEth exhibits near 100% specificity . Because its formation requires the enzymatic union of ethanol and cell-membrane phospholipids, it cannot be produced by incidental chemical exposures, environmental fumes, or non-alcoholic fermented foods. Furthermore, PEth values are completely unaffected by end-stage liver disease, renal impairment, age, or gender.

Clinical Interpretation Thresholds:

< 20 ng/mL <20\text{ ng/mL} < 20 ng/mL : Indicates complete abstinence or insignificant, light alcohol consumption within the past month.

20 to 200 ng/mL 20\text{ to }200\text{ ng/mL} 20 to 200 ng/mL : Indicates moderate, significant, or repeated alcohol consumption.

> 200 ng/mL >200\text{ ng/mL} > 200 ng/mL : Highly diagnostic of chronic, heavy alcohol consumption (typically > 4 >4 > 4 standard drinks or > 50 – 60 g >50\text{–}60\text{ g} > 50 – 60 g of pure ethanol daily for several weeks).

2. Ethyl Glucuronide (EtG) and Ethyl Sulfate (EtS)

Biochemistry: Less than 0.1% of ingested ethanol undergoes non-oxidative Phase II conjugation: EtG is formed via hepatic glucuronidation (UDP-glucuronosyltransferase), while EtS is formed via sulfation (sulfotransferase).

Detection Window: Measurable in urine within 1 to 2 hours of ingestion, persisting for 24 to 80 hours (up to 3 to 5 days following heavy binge episodes), long after parent ethanol has cleared from breath and blood.

Critical Clinical Caveat (Incidental Exposure): EtG is exceptionally sensitive. At low cutoffs ( 100 ng/mL 100\text{ ng/mL} 100 ng/mL ), false-positive results frequently occur from incidental, non-beverage ethanol exposure, including alcohol-based hand sanitizers, mouthwashes, cosmetics, aerosolized cleaning agents, and fermented non-alcoholic beverages (e.g., kombucha).

Cutoff Recommendations (SAMHSA Guidelines):

100 to 500 ng/mL 100\text{ to }500\text{ ng/mL} 100 to 500 ng/mL : High likelihood of incidental environmental exposure or remote light drinking.

≥ 500 ng/mL \ge 500\text{ ng/mL} ≥ 500 ng/mL : Highly consistent with recent intentional consumption of alcohol within the prior 24–48 hours.

≥ 1 , 000 ng/mL \ge 1,000\text{ ng/mL} ≥ 1 , 000 ng/mL : Recommended in forensic and professional licensing monitoring programs to definitively rule out false positives from incidental contact.

Bacterial Degradation: Certain urinary tract pathogens (e.g., Escherichia coli producing β \beta β -glucuronidase) can hydrolyze and degrade EtG in vitro, causing false-negative results. Because EtS is not susceptible to β \beta β -glucuronidase degradation, dual testing (EtG + EtS) is the standard of care.

Indirect Biomarkers

Indirect biomarkers measure secondary physiological, enzymatic, or hematological changes induced by sustained alcohol toxicity.

Carbohydrate-Deficient Transferrin (%CDT): Normal serum transferrin contains 4 to 6 sialic acid residues. Chronic heavy ethanol intake ( > 4 – 5 >4\text{–}5 > 4 – 5 standard drinks/day for ≥ 2 \ge 2 ≥ 2 consecutive weeks) directly inhibits glycosyltransferases and stimulates sialidase in hepatocytes, yielding transferrin isoforms with 0 to 2 sialic acid residues (disialo- and asialotransferrin). %CDT values > 1.7 – 2.0 % >1.7\text{–}2.0\% > 1.7 – 2.0% reflect heavy use. %CDT normalizes within 2 to 4 weeks of sustained abstinence. Limitations: Reduced sensitivity in females, premenopausal states, and end-stage biliary cirrhosis.

Gamma-Glutamyl Transferase (GGT): A biliary canalicular enzyme induced by chronic alcohol exposure. Displays high sensitivity (~75%) for heavy drinking, but very poor specificity , as GGT is routinely elevated by non-alcoholic fatty liver disease (NAFLD/NASH), obesity, biliary obstruction, and medications that induce hepatic microsomal enzymes (e.g., phenytoin, carbamazepine, barbiturates). Half-life is 2 to 3 weeks.

Mean Corpuscular Volume (MCV): Chronic alcohol exposure exerts a direct toxic effect on developing erythroblast membranes and alters membrane lipid composition, causing macrocytosis ( M C V > 100 fL MCV > 100\text{ fL} MC V > 100 fL ) without necessarily producing megaloblastic anemia. Because the lifespan of a circulating erythrocyte is 120 days , MCV normalizes very slowly over 2 to 3 months of sobriety, making it a poor marker for acute relapse.

AST/ALT Ratio ( > 2 : 1 >2:1 > 2 : 1 ): Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) elevations are hallmarks of hepatocellular injury. In alcohol-induced liver injury, the AST/ALT ratio exceeds 2 : 1 2:1 2 : 1 (and often exceeds 3 : 1 3:1 3 : 1 ). This occurs because (1) chronic alcohol suppresses hepatic pyridoxal 5'-phosphate (vitamin B 6 B_6 B 6 ​ ), a required coenzyme for ALT synthesis, blunting serum ALT elevations; and (2) alcohol induces direct mitochondrial membrane toxicity, preferentially releasing mitochondrial AST isoenzymes into circulation. Total AST in uncomplicated alcoholic hepatitis rarely exceeds 400 – 500 IU/L 400\text{–}500\text{ IU/L} 400 – 500 IU/L ; values > 1 , 000 IU/L >1,000\text{ IU/L} > 1 , 000 IU/L strongly suggest acetaminophen toxicity, ischemic hepatitis, or viral hepatitis.

Biomarker Comparison Reference Table

Biomarker Type Specimen Detection Window Specificity Clinical Utility & APRN Considerations

PEth Direct Whole blood (dried blood spot) 2 to 4 weeks (t½ 4–10 days) Near 100% Gold standard for heavy drinking ( > 4 >4 > 4 drinks/day); unaffected by liver/kidney disease or incidental exposure.

EtG / EtS Direct Urine 24 to 80 hours Moderate (cutoffs dependent) Detects recent intake; use cutoff ≥ 500 ng/mL \ge 500\text{ ng/mL} ≥ 500 ng/mL to exclude incidental hand-rub/mouthwash exposures; test both to detect bacterial degradation.

%CDT Indirect Serum 2 to 4 weeks Moderate-High Identifies sustained heavy consumption ( > 4 – 5 >4\text{–}5 > 4 – 5 drinks/day for 2+ weeks); normalizes after 2–4 weeks abstinence.

GGT Indirect Serum 2 to 3 weeks Poor (Low) Highly sensitive but non-specific; elevated by NAFLD, cholestasis, antiepileptics.

MCV Indirect Whole blood (CBC) 2 to 3 months Poor Macrocytosis ( > 100 fL >100\text{ fL} > 100 fL ); delayed normalization due to 120-day RBC lifespan.

AST/ALT Ratio Indirect Serum Days to weeks High for ALD if > 2 : 1 >2:1 > 2 : 1 Reflects B 6 B_6 B 6 ​ depletion (suppressing ALT) and mitochondrial AST release; AST usually < 500 IU/L <500\text{ IU/L} < 500 IU/L .